Published in J Virol on July 01, 1995
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol (1998) 1.99
Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol (2013) 1.74
Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1996) 1.70
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol (2000) 1.29
Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res (2009) 1.25
vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol (1996) 1.22
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol (2010) 1.10
Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. J Virol (1995) 1.09
Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats. J Virol (1996) 1.06
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol (1996) 1.04
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol (2002) 1.01
A strong case for viral genetic factors in HIV virulence. Viruses (2011) 1.01
Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1997) 0.99
Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol (1997) 0.97
CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol (1999) 0.96
Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission. J Virol (1998) 0.92
Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest (1997) 0.91
Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles. Virol J (2010) 0.89
Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J Virol (1998) 0.88
Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors. J Virol (2009) 0.86
Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection. PLoS One (2012) 0.84
The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PLoS One (2009) 0.82
Association of the HLA-B*52 allele with non-progression to AIDS in Brazilian HIV-1-infected individuals. Genes Immun (2014) 0.82
Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. J Virol (2001) 0.81
Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication. J Virol (2000) 0.79
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
Association of single nucleotide polymorphisms in the lens epithelium-derived growth factor (LEDGF/p75) with HIV-1 infection outcomes in Brazilian HIV-1+ individuals. PLoS One (2014) 0.75
Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication in vitro and Modulate HIV Restriction Factor Expression. J Virol (2017) 0.75
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Mutational analysis of the human immunodeficiency virus vpr open reading frame. J Virol (1989) 3.48
Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med (1993) 3.29
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology (1994) 3.16
Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. EMBO J (1993) 3.13
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet (1992) 2.60
CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc Natl Acad Sci U S A (1993) 2.51
Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol (1994) 2.20
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol (1995) 2.08
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS (1993) 2.00
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.00
Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1995) 1.95
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis (1991) 1.77
Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J Virol (1993) 1.77
Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol (1993) 1.63
Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr (1994) 1.58
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain. New Biol (1989) 1.47
HIV pathogenesis and long-term survival. AIDS (1993) 1.47
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses (1994) 1.45
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol (1994) 1.42
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology (1993) 1.32
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein. J Virol (1994) 1.27
Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology (1994) 1.25
In vivo genetic variability of the HIV-1 vif gene. Virology (1994) 1.18
CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration. EMBO J (1993) 1.17
Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis (1994) 1.12
Human immunodeficiency virus and acquired immunodeficiency syndrome: an update. Adv Intern Med (1994) 1.11
Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr (1994) 1.10
Specific suppression of human CD4 surface expression by Nef from the pathogenic simian immunodeficiency virus SIVmac239open. Virology (1994) 1.08
Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function. J Virol (1993) 1.07
Regulation of human immunodeficiency virus Nef protein by phosphorylation. Virology (1994) 0.91
The acute retroviral syndrome and the pathogenesis of HIV-1 infection. Semin Immunol (1993) 0.91
Down-regulation of CD4 molecules by the expression of Nef: a quantitative analysis of CD4 antigens on the cell surfaces. Int Immunol (1993) 0.83
Natural history of human immunodeficiency virus infection. Dermatol Clin (1991) 0.77
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. Science (1996) 9.34
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med (1996) 7.28
Human skin Langerhans cells are targets of dengue virus infection. Nat Med (2000) 5.74
Lac repressor genetic map in real space. Trends Biochem Sci (1997) 5.56
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry (1992) 3.55
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. EMBO J (1993) 3.13
HIV-1 suppression during acute scrub-typhus infection. Lancet (2000) 3.08
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang (2005) 2.47
Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J Virol (1998) 2.46
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38
Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr (1999) 2.28
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med (1993) 2.14
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Cardiac papillary fibroelastoma. Ann Thorac Surg (1995) 1.94
Questionable efficacy of confidential unit exclusion. Transfusion (1990) 1.81
Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med (2000) 1.79
Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol (2008) 1.79
Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion (1994) 1.78
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol (1997) 1.72
Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med (1997) 1.71
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol (1997) 1.63
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood (1999) 1.59
Societal responsibility for malpractice. Milbank Mem Fund Q Health Soc (1976) 1.57
A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis (1998) 1.57
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis (1999) 1.54
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol (1998) 1.51
Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med (1998) 1.50
Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. Eur J Heart Fail (2015) 1.49
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med (1999) 1.48
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Endovascular stent-graft treatment for Stanford type A aortic dissection. Eur J Vasc Endovasc Surg (2011) 1.47
Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion (2003) 1.47
ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis. J Clin Pathol (1999) 1.46
Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion (2001) 1.46
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 1.46
Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts. J Infect Dis (1997) 1.44
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion (2001) 1.43
Transfusion-transmitted arboviruses. Vox Sang (2009) 1.42
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion (2003) 1.41
Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS (2001) 1.40
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Reduction of human immunodeficiency virus-infected cells from donor blood by leukocyte filtration. Transfusion (1989) 1.38
Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion (1994) 1.38
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol (1999) 1.38
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol (1995) 1.37
Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA (2000) 1.37
Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail. Proc Natl Acad Sci U S A (1995) 1.37
'Feeling the pressure': structural insights into a gated mechanosensitive channel. Curr Opin Struct Biol (1999) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Demographic characteristics, unreported risk behaviors, and the prevalence and incidence of viral infections: a comparison of apheresis and whole-blood donors. The Retrovirus Epidemiology Donor Study. Transfusion (1998) 1.33
'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. AIDS (2000) 1.33
Mechanism of malic enzyme from pigeon liver. Magnetic resonance and kinetic studies of the role of Mn2+. J Biol Chem (1976) 1.32
Assessment of human immunodeficiency virus expression in cocultures of peripheral blood mononuclear cells from healthy seropositive subjects. J Med Virol (1988) 1.32
Characterization of subtype A HIV-1 from Africa by full genome sequencing. AIDS (1999) 1.31
Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.30
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol (1997) 1.30
Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J Virol (1994) 1.29
Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses (2002) 1.28
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol (1998) 1.27
Effect of platelet-associated virus on assays of HIV-1 in plasma. Science (1993) 1.26
Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis (1997) 1.24
False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA (1998) 1.24
NAT and blood safety: what is the paradigm? Transfusion (2000) 1.24
HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol (1998) 1.22
Heterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners. J Acquir Immune Defic Syndr (1994) 1.22
The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat (2008) 1.22
Evaluation of four alternative methodologies for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.22
Calcium requirements for increased complement receptor expression during neutrophil activation. J Immunol (1985) 1.21
Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem (1998) 1.21
Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry (1996) 1.21
A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1. J Acquir Immune Defic Syndr (1991) 1.21
Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat (2008) 1.21
Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.20